Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value
GLMDAn amendment to the Company's Articles of Association to increase the authorized share capital from 50,000,000 ordinary shares to 900,000,000 ordinary shares was approved at the Company's Special General Meeting of shareholders held on August 15, 2025 The Company is initially planning to...
Galmed Pharma Announces Discovery Of Proprietary PD Blood-Based Biomarker Signature For Aramchol, Clinically Advanced Stearoyl-Coa Desaturase 1 Inhibitor
GLMDGalmed Pharmaceuticals Q1 EPS $(0.62) Beats $(0.89) Estimate
GLMDGalmed Pharma: First Set Of Oncology Studies Show Aramchol Enhances Liver / Colorectal Cancer-approved Therapeutic Regorafenib Effects In Liver And Colon Cancers In-vitro And In-vivo Models
GLMDGalmed Pharmaceuticals Enters Sponsored Project Agreement With Virginia Commonwealth University To Evaluate Aramchol's Effect On Overcoming Drug Resistance In Gastrointestinal Cancers
GLMDGalmed Unveils Pharmacodynamic Blood Markers For Aramchol
GLMDGalmed Announces Part 1 Results From AM-001 Study Of Aramchol Meglumine, An Enhanced Formulation Of The Most Clinically Advanced SCD1 Inhibitor
GLMDMaxim Group Downgrades Galmed Pharmaceuticals to Hold
GLMDGalmed Pharmaceuticals Files Annual Report On Form 20-F For Fiscal Year Ended December 31, 2024
GLMDGalmed Pharmaceuticals Announces The Grant Of A New Patent Related To Aramchol; Patent Covers The Use Of A Combination Therapy Of Aramchol And Resmetirom For The Treatment Of Non-Alcoholic Steatohepatitis, Also Known As Metabolic Dysfunction-Associated St
GLMDGalmed Pharmaceuticals Shares Resumed Trade
GLMDGalmed Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 67.9%
GLMDGalmed Research And Development Granted U.S. Patent #12239712 Combination therapy for the treatment of liver disease
GLMDGalmed Pharmaceuticals Shares Halted On Circuit Breaker To Upside On Relatively Light Volume; Down 13%
GLMDRaymond James Maintains Outperform Rating for Galmed Pharmaceuticals: Here's What You Need To Know
GLMDRaymond James has decided to maintain its Outperform rating of Galmed Pharmaceuticals (NASDAQ:GLMD) and lower its price target from $14.00 to $5.00.
Shares of Galmed Pharmaceuticals are trading down 22.69% over the last 24 hours, at $0.94 per share.
HC Wainwright & Co. Downgrades Galmed Pharmaceuticals to Neutral
GLMDRaymond James Maintains Outperform on Galmed Pharmaceuticals, Lowers Price Target to $5
GLMDRecap: Galmed Pharmaceuticals Q4 Earnings
GLMDGalmed Pharmaceuticals (NASDAQ:GLMD) reported its Q4 earnings results on Monday, May 2, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Galmed Pharmaceuticals Q4 EPS $(0.30), Inline
GLMDGalmed Pharmaceuticals's Earnings Outlook
GLMDGalmed Pharmaceuticals (NASDAQ:GLMD) is set to give its latest quarterly earnings report on Monday, 2022-05-02. Here's what investors need to know before the announcement.
Analysts estimate that Galmed Pharmaceuticals will report an earnings per share (EPS) of $-0.30.
Galmed Reports Interim Results From The Open-Label Part Of The ARMOR Study With Aramchol Showing Robust Fibrosis Improvement Across Multimodality Histological Assessment
GLMD